The Effect of Radiographic Contrast Media on Reperfusion Injury in the Isolated Rat Heart

Soo Yong Lee, MD¹, Young Ho Jang, MD², Mi Young Lee, MD³, Jongmin Hwang, MD⁴, Sang Hyun Lee, MD⁴, Min Ku Chon, MD⁵, Sun Ae Hwang, MD⁴, Jeong Su Kim, MD⁴, Yong Hyun Park, MD⁴, Kook Jin Chun, MD⁴, and June Hong Kim, MD⁴

¹Department of Internal Medicine, Pusan National University Yangsan Hospital, Yangsan, ²Institute of Cancer Rehabilitation and Convalescence, Yoonsung Hospital, Cheongdo, ³Department of Preventive Medicine, Keimyung University School of Medicine, Daegu, ⁴Division of Cardiology, Department of Internal Medicine and Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Yangsan, ⁵Cardiovascular Research Laboratory, Pusan National University Yangsan Hospital, Yangsan, Korea

Background and Objectives: We investigated the effects of commonly used contrast media (CM) on myocardial ischemia-reperfusion injury in isolated rat hearts.

Subjects and Methods: Isolated rat hearts were subjected to 30 minutes of regional ischemia and 2 hours of reperfusion. The following CM (1 mL/1 L Krebs-Henseleit buffer) were randomly perfused for 15 minutes beginning 5 minutes before reperfusion and ending 10 minutes after reperfusion: iohexol (n=8), iopromide (n=8), ioversol (n=8), iomeprol (n=8), iopamidol (n=7), ioxaglate (n=8), and iodixanol (n=7). The effects of a direct bolus injection of undiluted iohexol, iopromide, or ioxaglate (each n=6) via the aortic root immediately prior to reperfusion were also evaluated. The area of necrosis, expressed as the percentage of the area at risk (AN/AR), and cardiodynamic variables were measured.

Results: The AN/AR of the control and experimental groups in the order described in methods was 33.7±6.4%, 30.3±7.4%, 34.7±12.6%, 29.2±10.2%, 20.9±7.6%, 22.6±8.7%, 18.8±7.9%, and 19.9±11.4%, respectively. Groups that received iomeprol and ioxaglate exhibited significantly decreased AN/AR values compared to those of control hearts (p=0.042 and p=0.013). No significant differences in the AN/AR were observed between control hearts and the groups injected with a single bolus of CM. No significant hemodynamic changes were noted after reperfusion among the groups.

Conclusion: The overall effects of the CM on coronary reperfusion were not deleterious, and better effects were noted in two CM groups. However, it is unclear whether this result was attributed to a specific physiochemical property of the CM. (Korean Circ J 2014;44(6):423-428)

KEY WORDS: Contrast media; Heart; Myocardial infarction; Myocardial reperfusion.

Introduction

Interventional cardiology commonly uses contrast media (CM), but the effects of commonly used CM on reperfusion injury have not been thoroughly evaluated. Many studies have compared the effects of CM on various organs, and the side effects of CM on kidneys have been studied. The increase if a CM is dimeric, has a higher osmolality, or if the total volume of CM is greater. The lack of experimental and clinical studies is quite surprising considering that the myocardium is supposed to be exposed to a CM immediately after coronary reperfusion. The purpose of this study was to investigate the direct effects of commonly used CM on ischemic hearts undergoing reperfusion and the possible mechanisms of these effects.
Subjects and Methods

Contrast media

The isolated rat hearts randomly received a monomer or dimer CM from one of the following three groups: 1) iohexol, a non-ionic and low-osmolality monomer CM (Omnipaque 350®, GE Healthcare, Piscataway, NJ, USA), iopromide (Ultravist 370®, Bayer Healthcare, Seoul, Korea), ioversol (Optiray 350®, Tyco Healthcare, Tokyo, Japan), iomeprol (Iomeron 350®, Bracco Imaging Korea, Seoul, Korea), or iopamidol (Pamiray 370®, Dong Kook Pharmacy, Seoul, Korea); 2) an ionic and low-osmolality dimer CM ioxaglate (Hexabrix 320®, Guerbet, Villepinte, France) or 3) a non-ionic iso-osmolality dimer CM iodixanol (Vispaque 320®, GE Healthcare, Piscataway, NJ, USA). The physiochemical properties of the CM are shown in Table 1 and Fig. 1. The osmolality and viscosity of Krebs-Henseleit (KH) buffer was 290 mOsm/kg H2O and 6.9 mPa·s at 37°C, and were cited previously.5,6

Ischemia–reperfusion procedure

The experimental procedures and protocols used in this study were reviewed and approved by our Institutional Animal Care and Use Committee. Male Sprague-Dawley rats (KOATECH Co., Cheongwon, Korea), weighing 280–330 g, were used. The rats received 50 mg/kg pentobarbital sodium (Entobar®, Hanlim Pharmacy, Yongin, Korea) and 300 IU heparin intraperitoneally. The hearts were isolated and perfused with modified KH buffer containing (all in mM) 118.5 NaCl, 4.7 KCl, 1.2 MgSO4, 1.8 CaCl2, 24.8 NaHCO3, 1.2 KH2PO4, and 10 glucose. All hearts were perfused within 30–40 seconds after excision and were allowed to stabilize for at least 20 minutes. Regional ischemia was induced by making a snare around the major trunk of the left coronary artery (LCA) or its prominent branches between the left atrial appendage and the right ventricular outflow tract. Reperfusion was initiated by releasing the ends of the snare. All hearts were subjected to 30 minutes of regional ischemia and 2 hours of reperfusion. Control (CON) hearts (n=7) received no intervention either before or after LCA occlusion. The CM were given by two concentration models.

Protocol 1 (1:1000 dilution)

The CM were dissolved in KH buffer (1 mL/1 L KH buffer) on the day of the experiment and perfused for 15 minutes starting 5 minutes before reperfusion and ending 10 minutes after reperfusion. The 1:1000 dilution was chosen to investigate the pharmacological effects of CM and minimize the effects of physiochemical properties such as osmolality and viscosity of each CM.

Protocol 2 (bolus injection)

Additional rat hearts (each n=6) received a single bolus of 3 mL pure iohexol (Iohexol-S group), iopromide (iopromide-S group), or ioxaglate (ioxaglate-S group) via the aortic root immediately before reperfusion to complement for the loss of physiochemical properties by diluting the CM.

Hemodynamic monitoring

Myocardial contractility was assessed by left ventricular developed pressure (LVDP). An air-bubble-free, KH buffer-filled latex balloon was inserted into the left ventricle (LV) of the isolated hearts through the left atrial appendage. Balloon volume was adjusted with the BIOPAC system (BIOPAC Systems Inc., Goleta, CA, USA) to provide

Table 1. Physiochemical properties of the contrast media

<table>
<thead>
<tr>
<th>Contrast media</th>
<th>Osmolality (mOsm/kg H2O)</th>
<th>Iodine content (mg I/mL)</th>
<th>Viscosity (mPa·s at 37°C)</th>
<th>Molecule</th>
<th>Charge</th>
</tr>
</thead>
<tbody>
<tr>
<td>Iohexol</td>
<td>640</td>
<td>300</td>
<td>10.4</td>
<td>Monomer</td>
<td>Non-ionic</td>
</tr>
<tr>
<td>Iopromide</td>
<td>780</td>
<td>370</td>
<td>9.5</td>
<td>Monomer</td>
<td>Non-ionic</td>
</tr>
<tr>
<td>Ioversol</td>
<td>792</td>
<td>350</td>
<td>9.0</td>
<td>Monomer</td>
<td>Non-ionic</td>
</tr>
<tr>
<td>Iomeprol</td>
<td>618</td>
<td>350</td>
<td>7.5</td>
<td>Monomer</td>
<td>Non-ionic</td>
</tr>
<tr>
<td>Iopamidol</td>
<td>796</td>
<td>370</td>
<td>9.4</td>
<td>Monomer</td>
<td>Non-ionic</td>
</tr>
<tr>
<td>Ioxaglate</td>
<td>580</td>
<td>320</td>
<td>7.5</td>
<td>Dimer</td>
<td>Ionic</td>
</tr>
<tr>
<td>Iodixanol</td>
<td>290</td>
<td>320</td>
<td>11.4</td>
<td>Dimer</td>
<td>Non-ionic</td>
</tr>
</tbody>
</table>

Fig. 1. Physiochemical properties of the contrast media (CM), particularly focusing on osmolality and viscosity. Note that ioxaglate 320 and iodixanol 320 have similar viscosity and osmolality.
and sustain a left ventricular end-diastolic pressure (LVEDP) of 5–10 mm Hg from the beginning of the experiment. The LVEDP was calculated as the difference between the left ventricular systolic pressure and the LVEDP. +dP/dt, was obtained using the analytical software (BSL v.3.7.3, BIOPAC Systems Inc., Goleta, CA, USA).

Measurement of infarct size

At the end of experiment, the area at ischemic risk (AR) and the necrotic area (AN) were demarcated with diluted fluorescent polymer microspheres (Duke Scientific Corp., Palo Alto, CA, USA) and 2,3,5-triphenyltetrazolium chloride (Sigma-Aldrich Chemical, St. Louis, MO, USA) stain. The AR and AN areas in the LV were quantified with UTHSCSA Image Tool ver. 3.0 and converted into volume by multiplying the areas by slice thickness (2 mm) with a rat heart slicer (Zivic Instruments, Pittsburgh, PA, USA). AN volume is expressed as a percentage of AR volume. All morphometric measurements were performed blind.

Statistical analysis

The infarct sizes in the experimental groups were compared to those in the CON group. Data are presented as means. AR and AN values for the iopromide-S, ioxaglate-S, and iohexol-S groups were 36.5±7.8%, 27.9±8.0%, and 27.3±5.7%, respectively. This protocol mimicked the actual primary percutaneous coronary intervention by shooting bolus CM via the aortic root. No significant difference in infarct size was observed between CON hearts (33.7±6.4%) and the experimental groups (Fig. 4, Table 2).

Hemodynamic results

Seventy-nine rat hearts were used for this experiment, and ventricular fibrillation (VF) occurred in 37 hearts (4/7 in CON, 5/8 in iohexol, 4/8 in iopromide, 4/8 in ioversol, 5/8 in iohexol-S, 3/7 in iopamidol, 5/8 in ioxaglate, 2/7 in iodiombl 2/7, 3/6 in iohexol-S, 3/6 in iopromide-S, and 2/6 in ioxaglate-S) during early reperfusion. A statistical analysis was not performed for the incidence of VF because of the

Protocol 1 (1:1000 dilution)

Among hearts that received monomer CM, iomipel (20.9±7.6%) significantly decreased the AN/AR value compared to that in CON hearts (p=0.042). The ionic dimer ioxaglate (18.8±7.9%) also significantly decreased AN/AR compared to that in CON hearts (p=0.013). A slight tendency to decrease infarct size was noted in the other CM groups, except the iopromide group (p>0.05) (Fig. 3, Table 2).

Protocol 2 (bolus injection)

AN/AR values for the iopromide-S, ioxaglate-S, and iohexol-S groups were 36.5±7.8%, 27.9±8.0%, and 27.3±5.7%, respectively. No significant difference in infarct size was observed between CON hearts (33.7±6.4%) and the experimental groups (Fig. 4, Table 2).

Results

Infarct size

No significant differences were observed in baseline LV mass, AR, AN, or AR/LV (%) between the CON and experimental groups. AR/LV ranged from 49.8% to 58.7% (p=0.05) (Table 2), suggesting that change in infarct volume was not related to the degree of ischemic volume. As shown in Table 2, AN/AR in CON hearts was 33.7±6.4%. Representative imaging data obtained during the infarct size measurements are shown in Fig. 2.

Table 2. Morphometric data

<table>
<thead>
<tr>
<th>Group</th>
<th>N</th>
<th>LV (cm³)</th>
<th>AR (cm³)</th>
<th>AN (cm³)</th>
<th>AR/LV (%)</th>
<th>AN/AR (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CON</td>
<td>7</td>
<td>0.73±0.08</td>
<td>0.37±0.04</td>
<td>0.13±0.03</td>
<td>51.5±6.8</td>
<td>33.7±6.4</td>
</tr>
<tr>
<td>Protocol 1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Iohexol</td>
<td>8</td>
<td>0.79±0.02</td>
<td>0.42±0.05</td>
<td>0.13±0.03</td>
<td>53.5±6.7</td>
<td>30.3±7.4</td>
</tr>
<tr>
<td>Iopromide</td>
<td>8</td>
<td>0.73±0.17</td>
<td>0.42±0.10</td>
<td>0.15±0.08</td>
<td>58.7±4.2</td>
<td>34.7±12.6</td>
</tr>
<tr>
<td>Ioversol</td>
<td>8</td>
<td>0.75±0.07</td>
<td>0.37±0.11</td>
<td>0.11±0.05</td>
<td>49.8±12.4</td>
<td>29.2±10.2</td>
</tr>
<tr>
<td>Iomeprol</td>
<td>8</td>
<td>0.76±0.04</td>
<td>0.40±0.07</td>
<td>0.08±0.03</td>
<td>53.0±8.8</td>
<td>20.9±7.6*</td>
</tr>
<tr>
<td>Iopamidol</td>
<td>7</td>
<td>0.77±0.11</td>
<td>0.45±0.10</td>
<td>0.10±0.04</td>
<td>57.1±7.0</td>
<td>22.6±8.7</td>
</tr>
<tr>
<td>Ioxaglate</td>
<td>8</td>
<td>0.75±0.13</td>
<td>0.42±0.07</td>
<td>0.08±0.04</td>
<td>57.1±11.8</td>
<td>18.8±7.9*</td>
</tr>
<tr>
<td>Iodixanol</td>
<td>7</td>
<td>0.67±0.05</td>
<td>0.39±0.04</td>
<td>0.08±0.04</td>
<td>57.8±4.6</td>
<td>19.9±11.4</td>
</tr>
<tr>
<td>Protocol 2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Iopromide-S</td>
<td>6</td>
<td>0.72±0.09</td>
<td>0.41±0.05</td>
<td>0.15±0.03</td>
<td>57.8±9.1</td>
<td>36.5±7.8</td>
</tr>
<tr>
<td>Ioxaglate-S</td>
<td>6</td>
<td>0.69±0.07</td>
<td>0.39±0.09</td>
<td>0.10±0.02</td>
<td>56.6±9.3</td>
<td>27.9±8.0</td>
</tr>
<tr>
<td>Iohexol-S</td>
<td>6</td>
<td>0.69±0.12</td>
<td>0.40±0.10</td>
<td>0.12±0.04</td>
<td>57.8±9.9</td>
<td>27.3±5.7</td>
</tr>
</tbody>
</table>

Values are means±standard deviations. Iohexol-S, Iopromide-S, and Ioxaglate-S indicate a single bolus injection of iohexol, iopromide, and ioxaglate, respectively *p<0.05 vs. CON. CON: untreated control hearts, LV: left ventricular mass, AR: area at ischemic risk, AN: area of necrosis.

http://dx.doi.org/10.4070/kcj.2014.44.6.423
small sample size. No significant differences were observed in baseline heart rate (HR), LVDP, or +dP/dt max among the groups (Table 3). Iodixanol preserved HR after reperfusion (p=0.041 vs. CON). However, no significant differences were observed among the groups for the other hemodynamic parameters after reperfusion.

**Discussion**

The harmful effects of CM on contrast-induced acute kidney injury (CIAKI) were described in terms of three factors: 1) direct toxicity of iodine, 2) higher osmolality, and 3) reduced flow rate due to viscosity.7,8 The higher the osmolality and viscosity of a CM, the greater the risk of CIAKI.7 Several interesting studies have been conducted to determine whether viscosity and osmolality, which are very important factors for CIAKI, also negatively affect ischemia-reperfusion injury.

Falck et al.10 reported a significant decrease in infarct size in isolated rat hearts that received repetitive injections of ioxaglate, io-
As shown in cases of CIAKI, laboratory data may not directly correlate with the patient outcome.

The effects of CM on coronary reperfusion after ischemia are expected to be harmful based on CIAKI. However, according to some studies, neither CM nor their physiochemical properties, which have been suggested to be harmful in CIAKI, have been demonstrated to be deleterious during ischemia reperfusion of isolated rat hearts.

None of the CM groups in this study showed decreased infarct size compared with that in the CON. We attempted to determine some of the possible effects of CM physicochemical properties, but no relationship among osmolality, viscosity, or infarction size was observed from the results of Protocol 2 (Supplementary Fig. 1 in the online-only Data Supplement).

Several adverse effects of various concentrations of iomepron on the human cardiovascular system were reported in 1993, including blood pressure fall/hypotension, bradycardia, angina pectoris, and shock. In contrast, another study investigated the effects of non-ionic iodinated CM (iomepron-350, ioxaglate-320) on hemodynamics of the human heart by intra-cardiac or intra-arterial injection but the results showed minimal effects of the CM on HR and LV pressure. The effect of CM on infarct size has not been reported in a human study. This may be because estimating the effect of CM on ischemia-reperfusion is limited when designing a study due to various confounding factors, such as platelets, drugs, ischemic time, or difficulties measuring infarct size.

### Limitations

Several limitations in this study should be discussed. First, we evaluated the effect of CM on reperfusion using the Langendorff model, in which the hemorheological factors of whole blood were excluded. The viscosity of whole blood and the interaction of the CM with the platelet system could play a role reducing infarct size. As shown in cases of CIAKI, laboratory data may not directly corre-
Contrast media are necessary in interventional cardiology. In particular, CM are the very first materials that reach the myocardium after reperfusion, but their effects have scarcely been reported. The effects of CM on ischemia reperfusion in our study were not deleterious, and better effects were noted in some groups. Further studies are needed to identify the mechanisms.

Acknowledgments
This study was supported by a Pusan National University Research Grant 2014.

Supplementary Materials
The online-only Data Supplement is available with this article at http://dx.doi.org/10.4070/kcj.2014.44.6.423.

References
Supplementary Fig. 1. Area of necrosis (AN) as a percentage of the area at risk (AR) according to osmolality (mOsm/kg H$_2$O) and viscosity (mPa · s at 37°C) of the contrast media (CM) in protocol 2. Osmolality and viscosity in the CON group are those of the KH buffer. Horizontal lines represent mean values of the results. No significant relationship was observed among osmolality, viscosity, and infarct size.